NCT06951880
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
Not Yet Recruiting
PHASE1Ages 18–55InterventionalTreatmentAstraZeneca
~160 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:AZD4916Placebo
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with adverse events (AEs)
Measured over From Screening (Day -29 to Day -2) up to 44 days
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
United Kingdom1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Healthy male and female participants with suitable veins for cannulation or repeated venipuncture.
All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective contraception.
Have a Body Mass Index between 18 and 30 kg/m2 inclusive and weigh at least 45 kg at Screening.
Part 2, Japanese participants only: Japanese participants must have been born in Japan, have 2 Japanese biological parents and 4 Japanese grandparents (as confirmed by the interview), and must not have lived outside of Japan for more than 10 years at the time of the Screening Visit.
Part 2, Chinese participants only: Chinese participants must have been born in China (including Hong Kong, Macau, and Taiwan), have 2 Chinese biological parents and 4 Chinese grandparents (as confirmed by the interview), and must not have lived outside of China for more than 10 years at the time of the Screening Visit.
Exclusion
History of any clinically important disease or disorder which, in the opinion of the Principal Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
History of chest irradiation, fibrosis, malignancy, surgical procedure, trauma or liver disease.
Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
Evidence of active tuberculosis or Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection.
Abnormal vital signs or clinically important abnormalities in rhythm.
Current smokers, known or suspected history of alcohol, drug abuse or caffeine intake.
History of severe allergy/hypersensitivity.
Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit.
Participants who are vegans or have dietary restrictions.
Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
What this trial measures
- Number of participants with adverse events (AEs)From Screening (Day -29 to Day -2) up to 44 days
The safety and tolerability of AZD4916 following oral administration of single-ascending doses and multiple-ascending doses to healthy participants (including Japanese and Chinese) will be assessed.